Revenues for 598 publicly held biotech companies grew 8.1% last year to $89.8 billion, compared to 10% in 2011. R&D expenditures increased 5.4% to $25.3 billion, compared to 9% in 2011. Revenues from US public firms increased 8.3% to $63.7 billion, and R&D spending grew 7.3% to $19.3 billion. In 2011, US public firms’ sales rose 12%, and R&D spending grew 9%. R&D expenses grew 17.3% among US firms with more than $500 million in revenues to $11.5 billion, but declined 4.9% among other firms to $7.8 billion. The number of private and public US companies totaled 2,175, down 4.1%. The capital raised by US public and private firms declined 25.2% and 2.4%, respectively. In 2012, 33% of US biotech companies had less than one year of cash available. In 2012, revenues for European biotech firms increased 7.6% to $20.4 million, but R&D spending fell 0.8% to $4.9 billion. The number of public and private European firms declined 2.6% to 1,964.

Source: Ernst & Young